menu
    • menu
    [{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Protagonist Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"JNJ-2113","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"JANSSEN BIOTECH","amount2":0.98999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.98999999999999999,"dosageForm":"Tablet","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Elektrofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"JANSSEN BIOTECH","amount2":0.79000000000000004,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.79000000000000004,"dosageForm":"Injection","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"LCB84","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"JANSSEN BIOTECH","amount2":1.7,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"Infusion","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Simcha Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"CAR T-based Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"JANSSEN BIOTECH \/ Janssen Biotech","highestDevelopmentStatusID":"14","companyTruncated":"JANSSEN BIOTECH \/ Janssen Biotech"}]

    Find Clinical Drug Pipeline Developments & Deals by JANSSEN BIOTECH

    Menu

    JANSSEN BIOTECH

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            JANSSEN BIOTECH

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Foundation Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves FoundationOne®Liquid CDx as Companion Diagnostic for AKEEGA®

                            Details : Akeega (niraparib, abiraterone acetate) is a tablet works by inhibiting approved for BRCA-mutated mCRPC in adults. The FDA has approved FoundationOne Liquid CDx as its companion diagnostic.

                            Brand Name : Akeega

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 01, 2024

                            Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Foundation Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            JANSSEN BIOTECH

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR T-based Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Simcha Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Simcha Therapeutics Licenses Decoy-Resistant IL-18 for Cell Therapy

                            Details : Under the terms of the agreement, Janssen will develop, manufacture, and commercialize CAR T-based cell therapy candidates with Simcha’s novel proprietary DR-18 for a set number of programs.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 08, 2024

                            Lead Product(s) : CAR T-based Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Simcha Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            JANSSEN BIOTECH

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Elektrofi

                            Deal Size : $793.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Elektrofi and Janssen Biotech Collaborate to Develop Formulation Technology Programs

                            Details : The collaboration focuses on developing an at-home subcutaneous version of a lead oncology asset and up to four additional targets using Elektrofi's formulation technology.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $18.0 million

                            January 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Elektrofi

                            Deal Size : $793.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            JANSSEN BIOTECH

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LCB84,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : LegoChem Biosciences

                            Deal Size : $1,700.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC

                            Details : Under the terms of the agreement, LCB will grant Janssen an exclusive, worldwide license for the development and commercialization of LCB84, a Trop2 directed ADC which is currently being investigated for advanced solid tumors.

                            Brand Name : LCB84

                            Molecule Type : Large molecule

                            Upfront Cash : $100.0 million

                            December 26, 2023

                            Lead Product(s) : LCB84,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : LegoChem Biosciences

                            Deal Size : $1,700.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            JANSSEN BIOTECH

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            JANSSEN BIOTECH

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JNJ-2113

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : Protagonist Therapeutics

                            Deal Size : $987.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ...

                            Details : Under the Agreement, Janssen is conducting Phase 2b trial of JNJ-2113 (formerly known as PN-235), a first-in-class targeted oral peptide designed to selectively block the IL-23 receptor, in moderately to severely active ulcerative colitis.

                            Brand Name : JNJ-2113

                            Molecule Type : Peptide

                            Upfront Cash : $50.0 million

                            December 13, 2023

                            Lead Product(s) : JNJ-2113

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : Protagonist Therapeutics

                            Deal Size : $987.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth